Article Text

other Versions

PDF
Demyelinating events in rheumatoid arthritis after drug exposures
  1. Sasha Bernatsky (sasha.bernatsky{at}mail.mcgill.ca)
  1. Research Institute of the McGill University Health Centre, Canada
    1. Christel Renoux
    1. Research Institute of the McGill University Health Centre, Canada
      1. Samy Suissa (samy.suissa{at}clinepi.mcgill.ca)
      1. Research Institute of the McGill University Health Centre, Canada

        Abstract

        Objective: To estimate biologic drug effects on risk of demyelinating events in rheumatoid arthritis (RA).

        Methods: Case-control analyses, nested in an administrative database cohort.

        Results: Initially, risk of demyelinating events appeared increased after anakinra drug exposure, and decreased after anti-TNF agents. However, this apparent differential risk was due to more anakinra use (and avoidance of anti-TNF agents), in persons at high risk for demyelinating events. In individuals not at high risk, the adjusted rate ratio after anti-TNF exposures was 1.31 (95% CI 0.68, 2.50) and after anakinra, 0.80 (0.29, 2.24).

        Conclusions: When accounting for differential prescription patterns, we noted a trend towards more events after anti-TNF exposures. When studying rare but important potential drug associations, pharmacoepidemiologic studies are valuable but must be carefully-done.

        Statistics from Altmetric.com

        Request permissions

        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.